AJU Pharm Co., Ltd.
15
3
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
33%
5 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers
Role: lead
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
Role: lead
A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study
Role: lead
A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults
Role: lead
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults
Role: lead
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults
Role: lead
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Role: lead
Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients
Role: lead
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
Role: lead
The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Role: lead
Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients
Role: lead
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers
Role: lead
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers
Role: lead
Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults
Role: lead
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2
Role: lead
All 15 trials loaded